Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02412787
Other study ID # SHP609-302
Secondary ID 2014-004143-13
Status Active, not recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date October 28, 2015
Est. completion date April 30, 2024

Study information

Verified date April 2024
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This extension study will allow participants that completed Study HGT-HIT-094 to continue receiving Elaprase treatment in conjunction with idursulfase IT or to continue receiving Elaprase treatment and begin concurrent IT treatment for those that did not receive idursulfase IT treatment in Study HGT-HIT-094.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 56
Est. completion date April 30, 2024
Est. primary completion date April 30, 2024
Accepts healthy volunteers No
Gender Male
Age group N/A to 18 Years
Eligibility Inclusion Criteria: - Participants must have completed Visit Week 52 assessments in Study HGT-HIT-094 (NCT02055118). - The participant's parent(s) or legally authorized guardian(s) must have voluntarily signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent form after all relevant aspects of the study have been explained and discussed. Consent of the participant's parent(s) or legally authorized guardian(s) and the participant's consent/assent, as relevant, must be obtained. - The participant has continued to receive Elaprase on a regular basis in Study HGT-HIT-094 (NCT02055118). Exclusion Criteria: - The participant has experienced, in the opinion of the investigator, a safety or medical issue that contraindicates treatment with idursulfase-IT, including, but not limited to, uncontrolled seizure disorder, bleeding disorder, and clinically relevant hypertension. - The participant has a known hypersensitivity to any of the components of idursulfase-IT. - The participant has clinically relevant intracranial hypertension. - The participant is enrolled in another clinical study, other than HGT-HIT-094 (NCT02055118), that involves clinical investigations or use of any investigational product (drug or [intrathecal/spinal] device) within 30 days prior to study enrollment or at any time during the study. - The participant has any known or suspected hypersensitivity to anesthesia or is thought to be at an unacceptably high risk for anesthesia due to compromised airways or other conditions. - The participant has a condition that is contraindicated as described in the SOPH-A-PORT® Mini S, Implantable Access Port, Spinal, Mini Unattached, with Guidewire (SOPH-A-PORT Mini S) intrathecal drug delivery device (IDDD) Instructions for Use, including: 1. The participant has had, or may have, an allergic reaction to the materials of construction of the SOPH-A-PORT Mini S device. 2. The participant's body size is too small to support the size of the SOPH-A-PORT Mini S Access Port, as judged by the investigator. 3. The participant's drug therapy requires substances known to be incompatible with the materials of construction. 4. The participant has a known or suspected local or general infection. 5. The participant is at risk of abnormal bleeding due to a medical condition or therapy. 6. The participant has 1 or more spinal abnormalities that could complicate safe implantation or fixation. 7. The participant has a functioning CSF shunt device. 8. The participant has shown an intolerance to an implanted device.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Idursulfase-IT
Participants will receive 10 mg of idursulfase-IT intrathecally via IDDD or LP once every 28 days. Participants who are younger than 3 years of age will receive an adjusted dose of 7.5 mg (>8 months to 30 months of age) and 10 mg (>30 months to 3 years of age).
Elaprase
Participants will receive intravenous (IV) Elaprase infusions at a minimum of 48 hours after IT administration of idursulfase-IT.

Locations

Country Name City State
Australia Women's and Children's Hospital Adelaide
Canada The Hospital for Sick Children Toronto Ontario
France Hôpital Femme Mère Enfants Bron
Mexico Instituto Nacional de Pediatría Coyoacan Ciudad De México
Spain Hospital Infantil Universitario Niño Jesus Madrid
United Kingdom Royal Manchester Children's Hospital Manchester
United States University of North Carolina Chapel Hill North Carolina
United States Ann & Robert H Lurie Children's Hospital of Chicago Chicago Illinois
United States Children's Hospital and Research Center at Oakland Oakland California

Sponsors (1)

Lead Sponsor Collaborator
Shire

Countries where clinical trial is conducted

United States,  Australia,  Canada,  France,  Mexico,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Adverse Events An adverse event is any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered investigational product-related. From start of study drug administration up to 121 months
Primary Number of Participants With Clinically Significant Changes in Vital Signs, Laboratory Parameters, and 12-lead Electrocardiogram (ECG) Findings Number of participants with clinically significant changes will be reported. From start of study drug administration up to 121 months
Primary Maximum Observed Serum Concentration (Cmax) of Idursulfase The Cmax of Idursulfase will be assessed. Baseline through Month 121
Primary Maximum Observed Concentration (Cmax) of Idursulfase in Cerebrospinal Fluid (CSF) The Cmax of Idursulfase in CSF will be assessed. Baseline through Month 121
Primary Change From Baseline in the Concentration of Glycosaminoglycan (GAG) in Cerebrospinal Fluid (CSF) Concentration of GAG in CSF will be assessed. Baseline through Month 121
Primary Change From Baseline in the Concentration of Glycosaminoglycan (GAG) in Urine Concentration of GAG in urine will be assessed. Baseline through Month 121
Primary Number of Participants who Report Anti-idursulfase Antibodies in Cerebrospinal Fluid (CSF) The presence of idursulfase-specific antibodies will be assessed. From start of study drug administration up to 121 months
Primary Number of Participants who Report Anti-idursulfase Antibodies in Serum The presence of idursulfase-specific antibodies will be assessed. From start of study drug administration up to 121 months
Secondary Change From Baseline in Differential Ability Scales, Second Edition (DAS-II) Standard Scores and Standard Cluster Scores The DAS-II will be used to assess all participants of age 2 years, 6 months or older. The DAS-II comprises 2 overlapping batteries. The Early Years battery is designed for children ages 2 years, 6 months through 6 years, 11 months. The Early Years battery is further divided into the Lower Level for children ages 2 years, 6 months through 3 years, 5 months and Upper Level for children ages 3 years 6 months through 6 years, 11 months. The School Age Battery is designed for children ages 7 years, 0 months through 17 years, 11 months. These batteries are fully co-normed for ages 5 years, 0 months, through 8 years, 11 months. The cluster areas include general conceptual ability (GCA), Verbal, Nonverbal, Spatial, and Special Nonverbal Composite (SNC). The cluster area score represents a score (mean = 100 and standard deviation of 15) on which higher scores indicate a higher level of cognitive ability. Baseline through Month 121
Secondary Change From Baseline in Age Equivalent Scores of the Bayley Scales of Infant Development, Third Edition (BSID-III) Domains Participants who are younger than 2 years, 6 months, will be assessed using the BSID-III. The BSID--III is a series of measurements to assess the motor (fine and gross), language (receptive and expressive), and cognitive development of infants and toddlers and consists of a series of developmental play tasks. Raw scores (range 40-160) will be converted to age- equivalent scores to measure ability, skill, and knowledge, expressed as the age at which most individuals reach the same level (age norm; range: 0, unbound). Baseline through Month 121
Secondary Change From Baseline in Development Quotient (DQ) of the Bayley Scales of Infant Development, Third Edition (BSID-III) Domains Participants who are younger than 2 years, 6 months, will be assessed using the BSID-III. The BSID--III is a series of measurements to assess the motor (fine and gross), language (receptive and expressive), and cognitive development of infants and toddlers and consists of a series of developmental play tasks. The development quotient (DQ) is a means to express a neurodevelopmental/cognitive delay which will be computed as a ratio and expressed as a percentage using the age equivalent score divided by the age at testing ([age-equivalent score/chronological age] × 100; range: 0-100). Baseline through Month 121
Secondary Change From Baseline in Standard Scores of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) Domains The VABS-II test measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. This test measures the following 4 key domains: communication, daily living skills, socialization, motor skills, and the adaptive behaviour composite (a composite of the other 4 domains). The standard scores represent a score (mean = 100 and standard deviation of 15) on which higher scores indicate a higher level of cognitive ability. Baseline through Month 121
Secondary Change From Baseline in Standard Composite Scores of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) Domains The VABS-II test measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. This test measures the following 4 key domains: communication, daily living skills, socialization, motor skills, and the adaptive behavior composite (a composite of the other 4 domains). The ABC score ranges from 20 to 160 on which higher scores indicate a higher level of adaptive functioning. A positive change value indicates improvement in adaptive functioning. Baseline through Month 121
Secondary Change From Baseline in Age Equivalents Score of the Differential Ability Scales, Second Edition (DAS-II) DAS-II will be used to assess all participants of age 2 years (Y), 6 months (M) or older. DAS-II comprises 2 overlapping batteries. Early Years Battery (EYB) is designed for ages 2Y,6M-6Y,11M. School Age Battery is designed for ages 7Y,0M-17Y,11M. These batteries are fully co-normed for age 5Y,0M-8Y,11M. Core subtests include Verbal (V) Comprehension, Picture Similarities, Naming Vocabulary, Pattern Construction (PC), Matrices (M) and Copying for DAS-II Early Y and Recall of Designs, Word Definitions, PC, M, Verbal Similarities, and Sequential and Quantitative Reasoning for DAS-II School Years. Standardized scores will be converted to age equivalent scores (AES) to measure ability, skill, and knowledge expressed as age at which most individuals reach same level. Mean AES will be obtained by averaging out AES. Higher score (HS) indicates greater cognitive ability (CA). Subtests score represent a score (mean=50 and standard deviation of 10) on which HS indicate a higher level of CA. Baseline through Month 121
Secondary Change From Baseline in Developmental Quotients (DQ) of the Differential Ability Scales, Second Edition (DAS-II) The DAS-II will be used to assess all participants of age 2 years (Y), 6 months (M) or older. The DAS-II comprises 2 overlapping batteries. The Early Years battery (EYB) is designed for children ages (CA) 2Y, 6M, through 6Y, 11M. The EYB is further divided into the Lower Level for CA 2Y, 6M through 3Y, 5M and Upper Level for CA 3Y, 6M through 6Y, 11M. The School Age Battery is designed for CA 7Y, 0M through 17Y, 1M. These batteries are fully co-normed for ages 5Y, 0M, through 8Y, 11M. The core subtests include Verbal Comprehension, Picture Similarities, Naming Vocabulary, Pattern Construction, Matrices, and Copying for the DAS-II Early Y and Recall of Designs, Word Definitions, Pattern Construction, Matrices, Verbal Similarities, and Sequential and Quantitative Reasoning for the DAS-II School Y. The DQ will be computed as a ratio and expressed as a percentage using the age equivalent score (AES) divided by the age at testing ([AES/chronological age] × 100; range, 0-100). Baseline through Month 121
Secondary Change From Baseline in T-scores of the Core Subtests Differential Ability Scales, Second Edition (DAS-II) The DAS-II will be used to assess all participants of age 2 years (Y), 6 months (M) or older. The DAS-II comprises 2 overlapping batteries. The Early Years battery (EYB) is designed for children ages (CA) 2Y, 6M, through 6Y, 11M. The EYB is further divided into the Lower Level for CA 2Y, 6M through 3Y, 5M and Upper Level for CA 3Y, 6M through 6Y, 11M. The School Age Battery is designed for CA 7Y, 0M through 17Y, 11M. These batteries are fully co-normed for ages 5Y, 0M, through 8Y, 11M. The core subtests (CS) include Verbal Comprehension, Picture Similarities, Naming Vocabulary, Pattern Construction, Matrices, and Copying for the DAS-II Early Years and Recall of Designs, Word Definitions, Pattern Construction, Matrices, Verbal Similarities, and Sequential and Quantitative Reasoning for the DAS-II School Years. The CS score represent a score (mean = 50 and standard deviation of 10) on which higher scores indicate a higher level of cognitive ability. Baseline through Month 121
Secondary Change From Baseline in Age Equivalents Score of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) Sub Domains The VABS-II test measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. This test measures the following subdomains of 5 key domains: Communication (Receptive, Expressive, Written), Daily Living Skills (Personal, Domestic, Community), Socialization (Interpersonal Relationships, Play and Leisure Time, Coping Skills), Motor Skills (Gross, Fine). The mean age equivalent score will be obtained by averaging out the age-equivalent scores for the all the sub-domains except for Gross and Fine motor skills (range: 0, unbound). Baseline through Month 121
Secondary Change From Baseline in Developmental Quotients (DQ) of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) Sub Domains The VABS-II test measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. This test measures the following subdomains of 5 key domains: Communication (Receptive, Expressive, Written), Daily Living Skills (Personal, Domestic, Community), Socialization (Interpersonal Relationships, Play and Leisure Time, Coping Skills), Motor Skills (Gross, Fine). The DQ will be computed as a ratio and expressed as a percentage using the age-equivalent score divided by the age at testing ([age-equivalent score/chronological age] × 100; range, 0-100). Baseline through Month 121
Secondary Change From Baseline in v-Scores of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) Sub Domains The VABS-II test measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. This test measures the following subdomains of 5 key domains: Communication (Receptive, Expressive, Written), Daily Living Skills (Personal, Domestic, Community), Socialization (Interpersonal Relationships, Play and Leisure Time, Coping Skills), Motor Skills (Gross, Fine). The V-scale scores represent a score (mean = 15 and standard deviation of 3; range: 1-24) on which higher scores indicate a higher level of adaptive functioning. Baseline through Month 121
Secondary Change From Baseline in v-Scale Scores of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) Maladaptive Behavior Index and its Subscales The VABS-II test measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. Maladaptive behavior index is a composite of the internalizing, externalizing, and other types of undesirable behavior that may interfere with the individual's adaptive functioning. The v-Scale scores represent a score (mean = 15 and standard deviation of 3; range: 1-24) on which higher scores indicate a higher level of adaptive functioning. Baseline through Month 121
Secondary Change From Baseline in Observed Maladaptive Levels of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) Maladaptive Behavior Index and its Subscales The VABS-II test measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. Maladaptive behavior index is a composite of the internalizing, externalizing, and other types of undesirable behavior that may interfere with the individual's adaptive functioning. The V scale scores represent a score (mean = 15 and standard deviation of 3; range: 1-24) on which higher scores indicate a higher level of cognitive ability. Baseline through Month 121
Secondary Change From Baseline in Brain Structure Volume as Measured by Magnetic Resonance Imaging (MRI) Brain structure volume will be assessed from brain total intracranial volume, brain total tissue volume, brain total white matter, brain total gray matter, and total CSF volume as measured by MRI. Baseline through Month 121
See also
  Status Clinical Trial Phase
Recruiting NCT05422482 - A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients With MPS Ⅱ Phase 1
Completed NCT00630747 - Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase Phase 2/Phase 3
Completed NCT03292887 - Hunter Outcome Survey (HOS)
Active, not recruiting NCT02455622 - Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age Phase 4
Completed NCT00882921 - An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients
Completed NCT00920647 - A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® Phase 1/Phase 2
Completed NCT01449240 - Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome
Completed NCT03920540 - A Study of GC1111 in Hunter Syndrom Patients Phase 3
Recruiting NCT06031259 - Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment Phase 2/Phase 3
Completed NCT02055118 - Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment Phase 2/Phase 3
Completed NCT01645189 - Safety and Efficacy of Hunterase Phase 3
Completed NCT00937794 - Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®
Recruiting NCT02171104 - MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis Phase 2
Recruiting NCT02044692 - The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients N/A
Completed NCT03582449 - Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701)
Completed NCT01822184 - Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)
Recruiting NCT05494593 - A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II) Phase 4
Completed NCT00607386 - Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy Phase 4
Completed NCT01043640 - Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders Phase 2
Terminated NCT01330277 - Biomarkers for Hunter Syndrome